Tecuro

Tecuro is a private, pre-revenue biotech firm pioneering a novel needle-free injection platform. The company's core technology, the Tecuro Injector, utilizes a high-speed liquid jet to deliver a wide range of therapeutics intradermally, subcutaneously, or intramuscularly without a needle, addressing significant unmet needs in patient compliance, safety, and precise dosing. Initially targeting the large and growing market for biologics and vaccines, Tecuro's platform has broad potential across multiple therapeutic areas. The company appears to be in a late development/pre-commercial stage, seeking partnerships to advance its lead programs toward regulatory approval and market entry.

Proprietary needle-free injection system using a high-speed liquid jet for precise intradermal, subcutaneous, or intramuscular delivery of therapeutics.

Tecuro competes in the needle-free injection space against companies like PharmaJet (tactile jet injector), Portal Instruments (connected needle-free device), and established players in auto-injectors (e.g., Ypsomed, SHL Medical). Its key differentiators are its focus on high-viscosity biologics, precise depth control, and a potentially simpler, more cost-effective device design.